Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment
NCT ID: NCT02473419
Last Updated: 2017-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
107 participants
OBSERVATIONAL
2015-05-31
2017-03-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation
NCT01924429
Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
NCT02257216
Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD
NCT04781972
An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD
NCT02259517
Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD
NCT01415440
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vayarin
Vayarin x 16 weeks
Vayarin
Placebo
Placebo x 16 weeks
Placebo
Vayarin and Placebo
Placebo x 8 weeks and then Vayarin x 8 weeks
Vayarin
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vayarin
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be willing and able to perform fMRI scanning
* Must maintain compliance to their trials' protocols
Exclusion Criteria
* implanted medical device (e.g., pacemaker)
* metal in the body that cannot be removed (e.g., braces)
* pregnancy
* concomitant use of anti-hypertensives or any other medications affecting the blood oxygenation level-dependent (BOLD) signal
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
New York University
OTHER
Enzymotec
INDUSTRY
The Medical Research Network
OTHER
Icahn School of Medicine at Mount Sinai
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeffrey Newcorn, MD
Role: PRINCIPAL_INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GCO 15-0399
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.